DERMATA THERAPEUTICS, INC.

DRMA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-7.6M $-12.3M $-7.8M $-9.6M $-7.9M $-3.2M
Depreciation & Amortization $0 $322
Depreciation
Amortization
Stock-Based Compensation $143.7K $657.6K $522.1K $930.3K $1.9M $0
Net Cash from Operating Activities $-7.8M $-11.2M $-6.4M $-8.8M $-5.7M $-4.0M
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $12.1M $6.9M $7.6M $4.3M $16.0M $2.6M
Net Change in Cash $4.4M $-4.3M $10.3M $-1.5M
Free Cash Flow